Nika Pharmaceuticals, Inc (NIKA) Income from Continuing Operations (2021 - 2023)
Nika Pharmaceuticals' (NIKA) quarterly Income from Continuing Operations came in at 10143.0 in Q3 2023, down 60.01% YoY from 25363.5 in Q3 2022, and up 63.52% on a QoQ basis from 27806.0 in Q2 2023.
Nika Pharmaceuticals, Inc (NIKA) Income from Continuing Operations (2021 - 2023) Analysis & Trends
Nika Pharmaceuticals (NIKA) has 3 years of Income from Continuing Operations data on file, last reported at 10143.0 in Q3 2023.
- Quarterly Income from Continuing Operations fell 60.01% year-over-year to 10143.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was 72569.0 (up 97.72% YoY) and the FY2022 annual result came in at 3183715.0, down 21540.26% from the prior year.
- Income from Continuing Operations climbed to 10143.0 in Q3 2023, from 27806.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6316.0 in Q1 2022 to a low of 3156010.0 in Q2 2022.
- A 3-year average of 295892.91 and a median of 10143.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 209.77% in 2022, down 106757.99% in 2022.
- Tracing NIKA's Income from Continuing Operations over 3 years: stood at 26124.0 in 2021, then soared by 42.39% to 15050.0 in 2022, then jumped by 32.6% to 10143.0 in 2023.
- The last three Income from Continuing Operations figures came in at 10143.0 (Q3 2023), 27806.0 (Q2 2023), and 19570.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -10,143.00 |
| Jun 30, 2023 | -27,806.00 |
| Mar 31, 2023 | -19,570.00 |
| Dec 31, 2022 | -15,050.00 |
| Sep 30, 2022 | -6,339.00 |
| Jun 30, 2022 | -3.16 Mn |
| Mar 31, 2022 | 6,316.00 |
| Dec 31, 2021 | -26,124.00 |
| Sep 30, 2021 | 2,699.00 |
| Jun 30, 2021 | 2,959.00 |
| Mar 31, 2021 | -5,754.00 |